missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human MAGEB4 (aa 26-149) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (42%), Rat (42%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-56478 (PA5-56478. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
This gene is a member of the MAGEB gene family. The members of this family have their entire coding sequences located in the last exon, and the encoded proteins show 50 to 68% sequence identity to each other. The promoters and first exons of the MAGEB genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEB genes are clustered on chromosome Xp22-p21. This gene sequence ends in the first intron of MAGEB1, another family member. This gene is expressed in testis.
Specifications
Specifications
| Accession Number | O15481 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 4115 |
| Name | Human MAGEB4 (aa 26-149) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | cancer/testis antigen family 3, member 6; CT3.6; MAGE family member B4; MAGEB4; MAGE-B4 antigen; melanoma antigen family B, 4; melanoma antigen family B4; melanoma-associated antigen B4; MGC33144 |
| Common Name | MAGEB4 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction